Drug development portfolio and spending practices after mergers and acquisitions

Drug Information Journal

Volumn 43, Issue 4, 2009, Pages 493-500

  Getz, Kenneth A ^b   Zuckerman, Rachael ^a   DiMasi, Joseph A ^a   Kaitin, Kenneth I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Acquisition; Development pipeline forecasting; M A; Merger

Indexed keywords

ARTICLE; DRUG INDUSTRY; DRUG RESEARCH; MERGERS AND ACQUISITIONS; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 68549092652     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150904300415     Document Type: Article

References (7)

1. Danzon P, Epstein A, Nicholson S. Mergers and acquisitions in the pharmaceutical and biotech industries. Managerial Decis Econ. 2007;28:307-328.
2. Whalen J, Winslow R. Cash-poor biotech firms cut research, seek aid. Wall Street J. October 29, 2008. Available at: http://online.wsj.com/article/ SB122523819921178005.html.
3. Graves S, Langowitz N. Innovative productivity and returns to scale in the pharmaceutical industry. Strategic Manage J. 1993;14:593-605.
4. Koenig M, Meezick E. Impact of mergers and acquisitions on research productivity within the pharmaceutical industry. Scientometrics. 2004;59(1):157-169. (Pubitemid 39109236)
5. Henderson L. The impact of mergers on clinical development. CenterWatch Monthly Newsletter. 2000;7(6):1-6.
6. The SCRIP 100. Annual SCRIP Supplement. London: Informa Healthcare; 2008:8-9. Available at: www.scrip100.com.
7. Dimasi JA. Risks in new drug development: approval success rates for investigation drugs. Clin Pharmacol Ther. 2001;69(5):297-307.